Amer Joseph
YOU?
Author Swipe
View article: Impact of Left Ventricular Assist Devices on the Quality of Life and Functional Outcomes in Advanced Heart Failure: A Comprehensive Review
Impact of Left Ventricular Assist Devices on the Quality of Life and Functional Outcomes in Advanced Heart Failure: A Comprehensive Review Open
[This corrects the article DOI: 10.7759/cureus.88527.].
View article: Impact of Left Ventricular Assist Devices on the Quality of Life and Functional Outcomes in Advanced Heart Failure: A Comprehensive Review
Impact of Left Ventricular Assist Devices on the Quality of Life and Functional Outcomes in Advanced Heart Failure: A Comprehensive Review Open
Managing advanced heart failure (HF) remains a major clinical challenge, especially for patients who no longer respond to conventional treatment options, or are not candidates for heart transplantation. In such cases, left ventricular assi…
View article: Extended long‐term efficacy and safety of velmanase alfa treatment up to 12 years in patients with alpha‐mannosidosis
Extended long‐term efficacy and safety of velmanase alfa treatment up to 12 years in patients with alpha‐mannosidosis Open
Enzyme replacement therapy (ERT) using velmanase alfa previously showed promising efficacy and safety outcomes for up to 4 years of therapy in patients with alpha‐mannosidosis. This pooled analysis from two multicenter, open‐label phase II…
View article: Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone Open
Importance It is currently unclear whether chronic kidney disease (CKD)–associated cardiovascular risk in type 2 diabetes (T2D) is modifiable. Objective To examine whether cardiovascular risk can be modified with finerenone in patients wit…
View article: Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888–897
Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888–897 Open
In Fig. 2 of the article cited above, due to a typographical error, the hazard ratio (HR) of the key secondary composite kidney outcome in the insulin at baseline subgroup was incorrectly reported as 0.74 (95% CI 0.59–0.94) instead of the …
View article: Cover Image
Cover Image Open
The outside front cover image is based on the Original Article Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at ba…
View article: Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes Open
Background Patients with stage 4 CKD and type 2 diabetes have limited treatment options to reduce their persistent cardiovascular and kidney risk. In Finerenone in Chronic Kidney Disease and Type 2 Diabetes (FIDELITY), a prespecified poole…
View article: Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of <scp>HbA1c</scp> at baseline, <scp>HbA1c</scp> variability, diabetes duration and insulin use at baseline
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of <span>HbA1c</span> at baseline, <span>HbA1c</span> variability, diabetes duration and insulin use at baseline Open
Aim To evaluate the effect of finerenone by baseline HbA1c, HbA1c variability, diabetes duration and baseline insulin use on cardiorenal outcomes and diabetes progression. Materials and Methods Composite efficacy outcomes included cardiova…
View article: Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis Open
Aims Finerenone reduces the risk of cardiovascular events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). We investigated the causes of mortality in the FIDELITY population. Methods and results The FIDELITY prespec…
View article: Front Cover
Front Cover Open
The outside front cover image is based on the Original Article Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use by Peter Rossing MD et al., https://doi…
View article: Supplementary Material for: Cardiorenal Outcomes With Finerenone in Asian Patients With Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD Post Hoc Analysis
Supplementary Material for: Cardiorenal Outcomes With Finerenone in Asian Patients With Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD Post Hoc Analysis Open
Introduction In FIDELIO-DKD, finerenone significantly improved cardiorenal outcomes in patients with chronic kidney disease and type 2 diabetes. This post hoc analysis explores finerenone in patients from the Asian region. Methods In FIDEL…
View article: Supplementary Material for: Cardiorenal Outcomes With Finerenone in Asian Patients With Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD Post Hoc Analysis
Supplementary Material for: Cardiorenal Outcomes With Finerenone in Asian Patients With Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD Post Hoc Analysis Open
Introduction In FIDELIO-DKD, finerenone significantly improved cardiorenal outcomes in patients with chronic kidney disease and type 2 diabetes. This post hoc analysis explores finerenone in patients from the Asian region. Methods In FIDEL…
View article: Supplementary Material for: Cardiorenal Outcomes With Finerenone in Asian Patients With Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD Post Hoc Analysis
Supplementary Material for: Cardiorenal Outcomes With Finerenone in Asian Patients With Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD Post Hoc Analysis Open
Introduction In FIDELIO-DKD, finerenone significantly improved cardiorenal outcomes in patients with chronic kidney disease and type 2 diabetes. This post hoc analysis explores finerenone in patients from the Asian region. Methods In FIDEL…
View article: Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes Open
Objective: Finerenone is a selective nonsteroidal mineralocorticoid receptor antagonist with a short half-life. Its effects on cardiorenal outcomes were thought to be mediated primarily via nonhemodynamic pathways, but office blood pressur…
View article: A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease Open
Background Mineralocorticoid receptor antagonists (MRAs) reduce systolic blood pressure (SBP) and increase serum potassium concentration ([K+]). This indirect comparison investigated any differences in SBP-lowering and hyperkalemia risk be…
View article: A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes Open
In FIDELITY, a prespecified pooled analysis of the FIDELIO-DKD and FIGARO-DKD studies, finerenone was found to improve cardiorenal outcomes in patients with type 2 diabetes, a urine albumin-to-creatinine ratio of 30-5000 mg/g, an estimated…
View article: Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease Open
Importance Patients with chronic kidney disease and type 2 diabetes have a higher risk of developing pneumonia as well as an increased risk of severe COVID-19–associated adverse events and mortality. Therefore, the anti-inflammatory effect…
View article: Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease Open
Aims Finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, improves cardiovascular (CV) and kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). This subgroup analysis of FIDELITY…
View article: Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes Open
Background: Chronic kidney disease is frequently associated with hypertension and poorly controlled blood pressure can lead to chronic kidney disease progression. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, significan…
View article: Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes Open
Compared with placebo, finerenone improved HF-related outcomes in patients with CKD and T2D, with consistent benefits across eGFR and/or UACR categories. (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diab…
View article: Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use Open
Aims To explore the modifying effect of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use on outcomes with finerenone across a wide spectrum of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in the pooled analysi…
View article: In patients with type 2 diabetes chronic kidney disease is a modifiable cardiovascular risk factor
In patients with type 2 diabetes chronic kidney disease is a modifiable cardiovascular risk factor Open
Background/Introduction Chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) is associated with an increased risk of cardiovascular (CV) events. The modifiability of CKD-associated CV risk in patients with T2D across a spect…
View article: Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis Open
OBJECTIVE Finerenone reduced the risk of kidney and cardiovascular events in people with chronic kidney disease (CKD) and type 2 diabetes in the FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049) phase 3 studies. Effects of finerenon…
View article: Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis Open
OBJECTIVE Finerenone reduced the risk of kidney and cardiovascular events in people with chronic kidney disease (CKD) and type 2 diabetes in the FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049) phase 3 studies. Effects of finerenon…
View article: Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis Open
OBJECTIVE Finerenone reduced the risk of kidney and cardiovascular events in people with chronic kidney disease (CKD) and type 2 diabetes in the FIDELIO-DKD and FIGARO-DKD phase 3 studies. Effects of finerenone on outcomes in patients taki…
View article: MO198: Outcomes with Finerenone in Patients with Stage 4 Chronic Kidney Disease and Type 2 Diabetes: A Fidelity Subgroup Analysis
MO198: Outcomes with Finerenone in Patients with Stage 4 Chronic Kidney Disease and Type 2 Diabetes: A Fidelity Subgroup Analysis Open
BACKGROUND AND AIMS Patients with stage 4 chronic kidney disease (CKD) and type 2 diabetes (T2D) have a high residual risk of cardiovascular (CV) and kidney disease progression, and effective treatment options to reduce the risk are limite…
View article: Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study Open
Background In FIGARO-DKD, finerenone reduced the risk of cardiovascular events in patients with type 2 diabetes (T2D) and stage 1–4 chronic kidney disease (CKD). In FIDELIO-DKD, finerenone improved kidney and cardiovascular outcomes in pat…
View article: Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the <scp>FIDELIO‐DKD</scp> trial
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the <span>FIDELIO‐DKD</span> trial Open
Aims This prespecified analysis of the FIDELIO‐DKD trial compared the effects of finerenone, a selective non‐steroidal mineralocorticoid receptor antagonist, on cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 …